Skip to main content
. 2021 Mar 9;2021(3):CD013522. doi: 10.1002/14651858.CD013522.pub2

Bloom 2017.

Study characteristics
Methods Study design: secondary analysis of RCT
Country: USA
Data collection period: not stated
Registry ID: not reported
Participants Number of participants: N = 61; Number included in meta‐analysis: N = not clear (somewhere between 48 and 51)
Sample characteristics (at baseline):
Age (mean): aerobic exercise (AE) group 47.1 years (SD 8.5), health education (HEC) group 47.5 years (SD 10.7); Sex (% male): AE 36.7% (11/30), HEC 32.3% (10/31)
Population category: general population; Specific population: adults who smoke and not recently engaged in aerobic exercise
Nicotine dependence: FTND AE 5.9 (SD 2.1), HEC 5.6 (SD 1.6); Baseline cigarettes per day: AE 20.3 (SD 9.9), HEC 19.4 (SD 8.1); Motivation to quit: selected by motivation to quit
Interventions Behavioural support for smoking cessation: all participants (AE and HEC) received 8 sessions of telephone counselling for smoking cessation
Pharmacological support for smoking cessation: all participants received 8 weeks of transdermal nicotine patch (TNP)
Psychotherapeutic or psychoactive support for mental health or mood: did not receive mood management
Outcomes Definition of cessation used: self‐reported 7‐day point prevalence abstinence at follow‐ups
Cessation definition used for outcome(s) in this analysis: point‐prevalence abstinence
Measure of biovalidation: expired carbon monoxide (CO; < 10 ppm cut‐off); in 1 instance, by the report of a family member of the participant because the participant was unable to provide CO
Definition of people who continued to smoke used: exact definition not reported; ‘continued smoking’, carbon monoxide > 10 ppm
Time point(s) at which follow‐up was conducted: 3 months (end of treatment), 6 months, and 12‐month follow‐up after baseline
Outcome category: Positive Affect; Psychological Quality of Life (QoL)
Outcome measure(s): QoL Enjoyment and Satisfaction Questionnaire – Short Form (Q‐LES‐Q‐SF; well‐being and satisfaction domains)
Funding source Supported by the National Institute on Drug Abuse (grant number K23 DA019950) awarded to Ana M. Abrantes, PhD
Author conflicts of interest No potential conflict of interest was reported by the authors
Notes Outcome data source: Published data